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Background: Malaria is the most prevalent communicable disease in Ethiopia, with 75% of the country’s landmass
classified as endemic for malaria. Accurate information on the distribution and clinical prevalence of Plasmodium
vivax and Plasmodium falciparum malaria in endemic areas, as well as in Duffy-negative populations, is essential to
develop integrated control strategies.
Methods: A total of 390 and 416 community and clinical samples, respectively, representing different localities and
age groups across Ethiopia were examined. Malaria prevalence was estimated using nested PCR of the 18S rRNA
region. Parasite gene copy number was measured by quantitative real-time PCR and compared between symptomatic
and asymptomatic samples, as well as between children/adolescents and adults from the local community. An
approximately 500-bp segment of the human DARC gene was amplified and sequenced to identify Duffy genotype
at the -33rd nucleotide position for all the clinical and community samples.
Results: Plasmodium vivax prevalence was higher in the south while P. falciparum was higher in the north. The
prevalence of P. vivax and P. falciparum malaria is the highest in children compared to adolescents and adults. Four
P. vivax infections were detected among the Duffy-negative samples. Samples from asymptomatic individuals show a
significantly lower parasite gene copy number than those from symptomatic infections for P. vivax and P. falciparum.
Conclusions: Geographical and age differences influence the distribution of P. vivax and P. falciparum malaria in
Ethiopia. These findings offer evidence-based guidelines in targeting malaria control efforts in the country.
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Malaria is the most prevalent communicable disease in
Ethiopia, with 75% of the country’s landmass classified as
malaria-endemic [1]. This disease has caused tremendous
human suffering and major negative effects on economic
productivity. From 2007 to 2008, malaria accounted for
10% of all hospital admissions and for ~15% of the overall
disability adjusted life years (DALYs) lost in the country* Correspondence: guiyuny@uci.edu
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unless otherwise stated.[1,2]. The malaria morbidity reported by the Ethiopian
Government and World Health Organization (WHO)
may underestimate the actual burden due to the lack
of epidemiological data, in addition to poor health
infrastructure and accessibility in the country [3,4]. The
problem is compounded by the presence of multiple
malaria parasite species [4,5], increasing drug resistance in
the parasites [6,7] and insecticide resistance in the
mosquito vectors [8,9]. Across the country, Plasmodium
falciparum and Plasmodium vivax account for approxi-
mately 60 and 40%, respectively, of infected cases [3-5].
Nonetheless, information on epidemiological significance,is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and P. vivax malaria in endemic areas is still insufficient.
Natural selection in malaria-endemic regions may have
favoured individuals who lack the Duffy blood group
antigen on the surface of their red blood cells because of
the conferred resistance to certain malaria parasites
[10-13]. The Duffy antigen receptor for chemokines
(DARC), also known as Fy glycoprotein, belongs to a
family of silent heptahelical chemokine receptors [10].
Plasmodium vivax and Plasmodium knowlesi require
this protein to infect red blood cells during their asexual
blood stage, while P. falciparum uses a different set of
receptors to gain access to the cell [14,15]. A point
mutation, T-33C, located in a GATA-1 transcription
factor-binding site of the DARC gene promoter can lead
to failure of Duffy antigen expression on the surface
of red blood cells in humans [10]. The absence of a
receptor for the pathogen confers resistance to P.
vivax malaria [10,16]. The rare presence of P. vivax
malaria in western or central Africa is likely attributed to
high Duffy-negativity among African blacks (88-100%)
[17,18]. However, this interpretation is challenged by
recent findings of P. vivax infection in Duffy-negative
people in different parts of Africa [19-24] and the
Brazilian Amazon region [25,26]. These data support
the hypothesis that P. vivax may have evolved the
capability to infect Duffy-negative red blood cells and
that the parasites are more prevalent and widespread
than reported previously.
There has been a number of population-based studies
of P. vivax infections in Duffy-negative individuals
among clinical and community samples [19-21,23-27].
Accurate information on the distribution and clinical
prevalence of P. vivax and P. falciparum malaria in
endemic areas, as well as in Duffy-negative populations, is
essential to develop integrated control strategies and to
more broadly evaluate the magnitude of the ‘derived’
P. vivax invasion. The present study defines the epi-
demiology of P. vivax and P. falciparum malaria in
large areas of Ethiopia with three specific questions:
(1) whether there are variations in the geographical
distribution of P. vivax and P. falciparum malaria
across Ethiopia; (2) is there a difference in the prevalence
of P. vivax and P. falciparum malaria between age groups
in local communities; and, (3) what is the frequency of P.
vivax infection in the Duffy-negative populations?
Furthermore, the parasite gene copy number between
symptomatic and asymptomatic infections of P. vivax and
P. falciparum were compared with the goal to evaluate
the performance of a quantitative real-time PCR (qPCR)
method for detecting high and low parasite density
samples. This is of key relevance in providing accurate
epidemiological data in local communities with mostly
asymptomatic infections.Methods
Ethics statement
Scientific and ethical clearance was obtained from the
institutional scientific and ethical review boards of Jimma
University, Ethiopia and University of California, Irvine,
USA. Written informed consent/assent for study participa-
tion was obtained from all consenting heads of households,
parents/guardians (for minors under age of 18), and each
individual who was willing to participate in the study.
Areas of study and sample collection
Clinical and community samples from six different local-
ities across Ethiopia were collected to determine malaria
prevalence (Figure 1). Finger-prick blood samples were col-
lected from a total of 416 malaria symptomatic or febrile
patients visiting the health centres or hospitals at each of
the localities (ranging from 41–125 patients per locality;
Table 1). In addition, blood samples were collected from
390 asymptomatic individuals representing the younger age
group, children and adolescents of age under 18 (n = 200),
and the older age group, adults of age 18 or above (n = 190)
from local communities of the Asendabo town (Figure 1).
A total of three to four spots of blood, equivalent to ~50 μl,
from each individual were blotted on Whatman 3MM filter
paper. Parasite DNA was extracted from dried blood spots
by the Saponin/Chelex method [28] and genomic DNA
was eluted in a total volume of 200 μl TE buffer.
Plasmodium species identification and quantification
A nested amplification of the 18S rRNA gene of
Plasmodium was performed to identify positive infection
and parasite species using published protocols [29,30].
Genomic DNA of each sample was amplified in duplicate
for verification. Amplification was conducted in a 20 μl
reaction mixture containing 2 μl of genomic DNA, 10 μl
of 2 × DreamTaqTM Green PCR Master Mix (Fermentas)
and 0.3 uM primer. Amplification reactions were per-
formed in a BIORAD MyCycler thermal cycler, with an
initial denaturation at 94°C for 2 min, followed by 35 cycles
at 94°C for 30 sec, 58°C for 30 sec and 65°C for 40 sec,
with a final 2-min extension at 65°C. A secondary
amplification was conducted in a 20 μl reaction mixture
containing 2 μl of product from the primary reaction and
the same PCR reagents (with the exception of forward and
reverse primers) and volume described above. The reac-
tions were performed with an initial denaturation at 94°C
for 2 min, followed by 35 cycles at 94°C for 20 sec, 58°C
for 20 sec and 65°C for 30 sec, with a final 2-min
extension at 65°C. The amplified products were resolved
electrophoretically on a 2.5% agarose gel in 0.5 ×
Tris-acetate buffer and visualized under UV light.
Parasite gene copy number was estimated using qPCR,
specifically the SYBR Green detection method [31] using
modified primers (forward: 5′-AGTCATCTTTCGAGGT
Figure 1 Map showing the geographical distribution of the sample sites in Ethiopia. Community samples were collected in Asendabo and
clinical samples were collected in the other six sites.
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CACGCCTGGTGGTGC-3′) specific to P. falciparum and
(forward: 5′-GAATTTTCTCTTCGGAGTTTATTCTTA
GATTGC-3′; reverse: 5′GCCGCAAGCTCCACGCCTG
GTGGTGC-3′) specific to P. vivax that targeted the 18S
rRNA genes. Based on the microscopic data, no P. malariae
or P. ovale was detected in the samples of the present study.
Therefore, the qPCR assay was performed to detect and
quantity P. falciparum and P. vivax only. Amplification was
conducted in a 20 μl reaction mixture containing 2 μl of
genomic DNA, 10 μl 2 × SYBR Green qPCR Master Mix
(Thermo Scientific), and 0.5 uM primer. The reactions were
performed in CFX96 TouchTM Real-Time PCR Detection
System (BIORAD), with an initial denaturation at 95°C for
3 min, followed by 45 cycles at 94°C for 30 sec, 55°C for
30 sec, and 68°C for 1 min with a final 95°C for
10 sec. This was followed by a melting curve step of
temperature ranging from 65°C to 95°C with 0.5°Cincrements to determine the melting temperature of
each amplified product. Each assay included positive
controls of both P. falciparum 7G8 (MRA-926) and
HB3 (MRA-155) isolates as well as P. vivax Pakchong
(MRA-342G) and Nicaragua (MRA-340G) isolates, in
addition to negative controls, including uninfected
samples and water. A standard curve was produced
from a ten-fold dilution series of the control plasmids
(P. falciparum and P. vivax) and laboratory culture
(P. falciparum) ranging from 1 to 1.75 × 10−12% para-
sitaemia to determine the efficiency and detection limit of
the qPCR. Melting curve analyses were performed for
each amplified sample to confirm specific amplifications
of the target sequence. The slope of the linear regression
of threshold cycle number (Ct) versus log10 (gene copy
number) was used to calculate amplification efficiency of
each plate run based on internal standard controls. For
the measure of reproducibility of the threshold cycle
Table 1 Distribution and prevalence of Plasmodium vivax (Pv) and Plasmodium falciparum (Pf) infections among the
clinical samples collected from the six health-centres/hospitals across Ethiopia
Locality Duffy phenotype Number of samples Total infection Number of Pv infection Number of Pf infection Number of Pv
and Pf infection
Bure
Positive 54 52 (96.3%) 30 (55.6%) 14 (25.9%) 8 (14.8%)
Negative 7 4 (57.1%) 0 (0%) 4 (57.1%) 0 (0%)
Halaba
Positive 66 17 (25.7%) 13 (19.7%) 2 (3%) 2 (3%)
Negative 20 1 (5%) 0 (0%) 1 (5%) 0 (0%)
Jimma
Positive 117 117 (100%) 93 (79.5%) 13 (11.1%) 11 (9.4%)
Negative 8 7 (87.5%) 0 (0%) 6 (75%) 1 (12.5%)
Mankush
Positive 29 26 (89.7%) 7 (24.1%) 18 (62.1%) 1 (3.4%)
Negative 21 16 (76.2%) 0 (0%) 15 (71.4%) 1 (4.8%)
Metehara
Positive 33 33 (100%) 14 (42.4%) 14 (42.4%) 5 (15.2%)
Negative 20 18 (90%) 0 (0%) 18 (90%) 0 (0%)
Shewa Robit
Positive 23 23 (100%) 7 (30.4%) 12 (52.2%) 4 (17.4%)
Negative 18 17 (94.4%) 0 (0%) 17 (94.4%) 0 (0%)
Total 416 331 164 134 33
Numbers in bold denote the number of individuals infected with P. vivax and have the Duffy-negative phenotype.
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lated from three independent assays of each sample. A
cut-off threshold of 0.02 fluorescence units that robustly
represented the threshold cycle at the log-linear phase of
the amplification and above the background noise was set
to determine Ct value for each assay. Samples yielding Ct
values higher than 40 (as indicated in the negative
controls) were considered negative for Plasmodium
species. The amount of parasite density in a sample was
quantified by converting the threshold cycle (Ct) into
gene copy number (GCN) using the follow equation:
GCNsample = 2
E×(40-Ctsample); where GCN stands for
gene copy number, Ct for the threshold cycle of the
sample, and E for amplification efficiency. Mean and
standard deviation values of the log-transformed parasite
GCN of samples from each of the sites were reported. The
differences in the log-transformed parasite GCN between
age groups as well as between symptomatic and asymp-
tomatic samples were assessed for significance at the level
of 0.05 by one-tailed t-tests. Variations in GCN among
samples were presented as boxplots showing the median
and interquartile range values. For the latter comparison,
only the symptomatic samples from Jimma and asymptom-
atic samples from Asendabo were included because these
two sites are in the same area so that difference in parasite
GCN would not be affected by geographical difference.DARC gene sequencing
An ~500-bp fragment of the human DARC gene that
encompasses the -33rd nucleotide position located in
the promoter region was amplified and sequenced using
published protocols [11]. Amplifications were conducted
in a 20 μl reaction mixture containing 2 μl of genomic
DNA, 10 μl of 2 × DreamTaqTM Green PCR Master Mix
(Fermentas) and 0.3 uM primer. The reactions were
performed in a BIORAD MyCycler thermal cycler, with
an initial denaturation at 94°C for 2 min, followed by
35 cycles at 94°C for 30 sec, 58°C for 30 sec, and 65°C
for 40 sec, with a final 2-min extension at 65°C in the
primary amplification. Amplicons were purified with USB
ExoSAP-IT (Affymetrix) followed by direct sequencing
with the forward and reverse primers using the BigDye
Terminator v3.1 cycle sequencing kit (Applied Biosystems)
on a 3130xl DNA analyzer (Applied Biosystems) according
to manufacturer’s instructions.
Results
Distribution and frequency of Plasmodium vivax and
Plasmodium falciparum infections among the
Duffy-positive and -negative individuals
A total of 94 of the 416 (~23%) clinical samples collected
from the six health centres/hospitals were homozygous
for the CC genotype at the -33rd nucleotide position
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(~26%) were homozygous TT, and 214 (~51%) were
heterozygous CT yielding 322 (~77%) Duffy-positive
samples. Two of the 94 Duffy-negative samples were
positive for P. vivax, one from the hospital in Jimma and
the other one in Mankush (number in bold; Table 1).
Based on the nested and quantitative PCR assays, these
two infected samples were mixed infections that contain
both P. vivax and P. falciparum. Compared to P. vivax
infection, the prevalence of P. falciparum infection
among the Duffy-negative samples was considerably
higher (an average prevalence of 41%; Table 1), with
the lowest prevalence observed from the clinical samples
in Halaba (5%) and the highest prevalence in Shewa
Robit (94%).
Three of the six health centres (Bure, Halaba and
Jimma) showed a higher prevalence of P. vivax than P.
falciparum infection for the Duffy-positive samples
(Table 1). In Jimma, the prevalence of P. vivax infection
was ≤ five-fold higher than that of P. falciparum. By
contrast, the prevalence of P. falciparum was ≤ three-fold
higher than that of P. vivax in Mankush and Shewa Robit
(Table 1). In Metehara, an equal number of P. vivax and
P. falciparum-infected cases was detected among the
Duffy-positives. A total of 31 (11.6%) of the 268 infected
cases in the Duffy-positives were mixed infections of both
P. vivax and P. falciparum.
Among the community samples, 139 out of 390 (35.6%)
were shown to be Duffy-negative and this proportion wasTable 2 Prevalence of Plasmodium vivax (Pv) and Plasmodium
community samples collected in Asendabo, Ethiopia
Age group Number of samples Total infection Number of P
0-5 years old
Duffy-positive 48 23 (47.9%) 10 (20.8%)
Duffy-negative 24 0 0
Total 72 23 (31.9%) 10 (13.9%)
6-18 years old
Duffy-positive 76 11 (14.5%) 7 (9.2%)
Duffy-negative 52 7 (13.5%) 1 (1.9%)
Total 128 18 (14.1%) 8 (6.3%)
Above 18 years old
Duffy-positive 127 21 (16.5%) 4 (3.1%)
Duffy-negative 63 11 (17.5%) 1 (1.6%)
Total 190 32 (16.8%) 5 (2.6%)
Combined all age
groups
Duffy-positive 251 55 (21.9%) 21 (8.4%)
Duffy-negative 139 18 (12.9%) 2 (1.4%)
Total 390 73 (18.7%) 23 (5.9%)
Numbers in bold denote the number of individuals infected with P. vivax and havesignificantly higher than the clinical samples (χ2 = 16.67,
d.f. = 1, P < 0.0001; Table 2). The proportion of Duffy-
negativity was comparable among children (24/72; 33.3%),
adolescents (52/128; 40.6%), and adults (63/190; 33%;
Tables 2). In general, the prevalence of P. falciparum was
higher than that of P. vivax in both the Duffy-positive and
Duffy-negative samples, with the exception of the Duffy-
positive adolescents (aged 6–18) that showed a higher
P. vivax (9.2%) than P. falciparum (3.9%) prevalence
(Table 2). None of the 24 Duffy-negative children
(aged 0–5) were detected with P. vivax or P. falciparum
infections (Table 2). Among the 52 Duffy-negative adoles-
cents, one was infected by P. vivax (1.9%) and six were
infected by P. falciparum (11.5%). No mixed infections
were detected among these samples. Likewise, in adults,
one of the 63 Duffy-negative samples was infected by P.
vivax (1.6%) and ten were infected by P. falciparum
(15.9%; Table 2). No mixed infections were detected.
Infection prevalence and parasite gene copy number
among age groups
The overall parasite prevalence in children aged from
0–5 (31.9%) was the highest among the three age
groups in the community samples (adolescents: 14.1%;
adults: 15.8%; Table 2). The prevalence of P. vivax infec-
tions in children (13.9%) was > two-times higher than in
adolescents (6.3%) and > five-times higher than in adults
(2.6%; Table 2). Among the P. falciparum infected samples,
prevalence was the highest in children (18.1%) followed byfalciparum (Pf) asymptomatic malaria among the




3 (3.9%) 1 (1.3%)
6 (11.5%) 0




33 (13.1%) 1 (0.4%)
16 (11.5%) 0
49 (12.6%) 1 (0.3%)
the Duffy-negative phenotype.
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small sample size of P. vivax infection detected in the
community samples (Table 2), the P. vivax gene copy
number in children (mean GCN and standard deviation:
1.51 ± 1.23/μl) and adolescents (1.08 ± 0.24/μl) were
significantly higher than that in adults (0.49 ± 0.80/μl)
(P < 0.05; Figure 2A). For P. falciparum, no significant
difference was found in the parasite GCN among the
three age groups (Figure 2A). Among the infected
community samples, only one individual (from the
adolescent aged 6–18) was found to contain both P. vivax
and P. falciparum (Table 2). The proportions of P.Figure 2 Box plots of the log-transformed parasite gene copy numbe
log-transformed parasite gene copy number of Plasmodium vivax and Plasm
age under 18 and adults of age 18 and above. These samples represent th
log-transformed parasite gene copy number of clinical Plasmodium vivax a
from the six health centre/hospital sites in Ethiopia. The central box represe
and fourth quartiles of the data. The median is shown as a line through th
P-values (above) are provided for the comparison of gene copy number be
Numbers (bottom) indicate the number of individuals included.falciparum infection were slightly higher than P. vivax in
both the children and adolescents; and this difference was
substantial in adults where the majority of the infections
are P. falciparum.
Compared to the community samples, the clinical
samples had a relatively small sample size for the three
age groups from each of the sites (Additional file 1). This
precluded any meaningful comparison of infection rate
among age groups. When all clinical samples were
combined, children (34.2%) showed a slightly higher
prevalence of P. vivax compared to adolescents (32.8%)
and adults (28.7%). Nonetheless, the prevalence of P.r of the community and clinical samples. (A) Box plot of the
odium falciparum measured by qPCR in children/adolescents of
e local community of Asendabo, Ethiopia. (B) Box plot showing the
nd Plasmodium falciparum cases in children/adolescents and adults
nts the interquartile range and the vertical lines represent the first
e centre of the box. Outlier samples are represented by open circles.
tween the two age groups with respect to P. vivax and P. falciparum.
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Both the P. vivax (children: 2.86 ± 1.01/μl; adolescents:
2.86 ± 1.22/μl; and adults: 2.80 ± 1.00/μl) and P. falciparum
GCN (children: 3.14 ± 1.54/μl; adolescents: 3.16 ± 1.15/μl;
and adults: 2.92 ± 1.11/μl) were not significantly dif-
ferent among the three age groups in the clinical samples
(Figure 2B).
Comparisons of parasite gene copy number between
symptomatic and asymptomatic infections
qPCR analyses revealed a significant difference in the
parasite GCN among the asymptomatic (community)
and symptomatic (hospital) infections for both P. vivax and
P. falciparum (Figure 3). Symptomatic P. vivax infections
showed a mean GCN of 3.45 ± 0.69/μl, which was signifi-
cantly higher than that observed in the asymptomatic P.
vivax infections (mean GCN of 1.30 ± 0.82/μl; Figure 3).
Similarly, symptomatic P. falciparum infections showed a
mean GCN of 2.48 ± 1.29/μl, which was higher than that in
the asymptomatic P. falciparum infections (mean GCN
1.13 ± 0.41/μl; Figure 3). No significant differences were
detected for the P. vivax and P. falciparum GCNs in the
symptomatic samples derived from the six sites across
Ethiopia (Additional file 2).Figure 3 Box plot of the log-transformed parasite gene copy
number of Plasmodium vivax and Plasmodium falciparum
measured by qPCR in asymptomatic and symptomatic samples
from Asendabo (community) and Jimma (hospital), respectively.
The central box represents the interquartile range and the vertical lines
represent the first and fourth quartiles of the data. The median is shown
as a line through the centre of the box. Outlier samples are represented
by open circles. The gene copy number of P. vivax detected in the four
Duffy-negative individuals are indicated by crosses in red. Numbers
(top) indicate the number of individuals included. P-values (below) are
provided for the comparison of gene copy number between
asymptomatic and symptomatic samples with respect to P. vivax and
P. falciparum.A total of four Duffy-negatives samples derived from
both the community (site Asendabo) and clinic (sites
Jimma and Mankush) were positive for P. vivax infections
(Tables 1 and 2). These samples have a mean GCN of
0.66 ± 0.64/μl (Figure 3), well at the lower limit of the
range of P. vivax GCN observed in Duffy-positive samples
(a mean GCN of 3.04 ± 1.06/μl). The substantial difference
in size, n = 4 and n = 210, of P. vivax infections in
Duffy-negative and -positive samples, respectively,
precludes any meaningful test of significance of the
GCN. For P. falciparum, the comparison of parasite
GCN indicated no significant difference between
Duffy-positive and Duffy-negative individuals regardless of
whether samples from all sites were analysed together or
separately (P > 0.05).
Discussion
Approximately 35% (139/390) and 22% (94/416) of the
community and clinical samples analysed in this study
are negative for the Duffy antigen. The proportion of
Duffy-negatives observed in the clinical samples is similar
to an earlier study that reported an average of 20%
homozygous Duffy-negative patients in Harar and
Jimma [23]. In contrast, the proportion of Duffy-negatives
observed in the community is over one-third more than
that in the clinical samples. However, these findings are
still lower than the proportion of Duffy-negatives
documented in West and Central Africa (>97%) [17,18].
Four P. vivax infections were identified among the
Duffy-negative samples, one of which was from
Jimma, one from Mankush, and the other two from
Asendabo. Two of these infected samples were obtained
from individuals with malaria symptoms and had mixed
infections; and qPCR showed that all these samples had a
relatively low number of parasite gene copy. These
findings confirm previous studies that documented a
number of P. vivax infections in Duffy-negative individuals
in Cameroon [19], Madagascar [20], Angola [21], Equatorial
Guinea [21], Ethiopia [23], Mauritania [24], as well as the
Brazilian Amazon region [25,26]. Although these studies
collectively are consistent with the conclusion that Duffy-
negative individuals are not completely resistance to P.
vivax infection, the observation of low P. vivax GCN in the
present Duffy-negative samples supports the hypotheses
that the infectivity of the parasite to human erythrocyte is
reduced in the absence of the Duffy antigen. It is worth
mentioned that the identification of Duffy phenotypes was
inferred solely based on the DARC genotypes but without
direct measure of antigen expression phenotypes of the
erythrocytes. Thus it is not entirely impossible for a Duffy
receptor to be present on the erythrocyte surfaces of a
genotypically Duffy-negative individual and that the P.
vivax strains use such to invade the erythrocytes of Duffy
negatives in this study.
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Duffy-negatives is not yet fully understood [11,13,32].
Apart from the Duffy antigen, there are several
tryptophan-rich antigens that play important role to the
survival and growth of malarial parasites in the host
[33-35]. For example, one of the P. vivax tryptophan-rich
antigens PvTRAg33.5 has been previously shown to
induce immune responses in humans and binds to host
erythrocytes [36]. Recently, 10 of 36 PvTRAgs of the
Pv-fam-a family were reported to possess erythrocyte-
binding activity [35]. Based on transcriptome data, a num-
ber of the erythrocyte-binding PvTRAgs including PvTRAg,
PvTRAgs, PcTRAg36.6, and PvTRAg69.4 were found in the
early stage of the parasite and involve in the rosetting
phenomenon [35]; while others including PvTRAg35.2,
PvTRAg38, PvTRAg36, and PvTRAg34 were found to
express at the late merozoite stage of the parasite that can
recognize more than one erythrocyte receptor and help the
parasite to invade the host erythrocytes [35]. It appears that
the binding of each of the antigens/ligands to different
receptors as well as the recognition of each receptor by
more than one parasite ligand could be advantageous
to P. vivax. The parasite can use the redundancy in
the receptor-ligand interaction as an alternate inva-
sion pathway or for tightly binding to its host cell
during the invasion or rosetting process even in the absence
of a Duffy receptor on the erythrocyte surfaces. It merits
further investigations on whether the alternate receptor-
ligand interactions that allow erythrocyte invasion evolve
independently among the P. vivax lineages and whether the
newly derived P. vivax strain has spread among endemic
regions subsequent to its emergence.
The geographical distribution of the two Plasmodium
species varies among sites in Ethiopia. Sites in the southwest
(Halaba and Jimma) had a greater proportion of P. vivax
than P. falciparum infections, whereas sites in the north
(Mankush and Shewa Robit), with the exception of Bure,
had a greater proportion of P. falciparum than P. vivax
infections. The predominance of either Plasmodium species
was reported previously in other parts of the country
[23,37-39], and this appears to be dependent on the study
population and the season of sampling. Samples of this
study were collected from September-November 2013,
during the peak season of malaria transmission in Ethiopia.
It is unlikely that the difference in the distribution of the
two Plasmodium species is due to seasonal characteristics
of Plasmodium infection in Ethiopia, but rather to the vari-
ation in climatic conditions among sites [3,40,41]. Despite
the fact that the studied area was set in the highlands, sites
at lower latitudes (Halaba and Jimma) may experience
warmer and more humid weather than sites at higher
latitudes (Mankush and Shewa Robit); such climatic varia-
tions may influence transmission and distribution of the
Plasmodium species. Another possible explanation is thatdifference in the age distribution of the infected individuals
may in part influence the distribution of the two
Plasmodium species. While such an effect is demon-
strated by the community samples that indicated a greater
prevalence of P. vivax infection in children and adolescents
than in adults, the prevalence among the clinical samples
were not significantly different between the two age groups.
Complicated and severe clinical malaria as well as the
prevalence of asymptomatic infections have been previously
shown to be highest in young children [42-44]. The
acquisition of immunity is age-dependent and young
children are most represented among malaria-diagnosed
deaths in many African countries [45]. Consistent with
previous findings, the present study shows that children
aged from 0–5 years old have the highest P. vivax (13.9%)
and P. falciparum prevalence (18.1%) than in adolescents
(6.3% and 7%, respectively, for P. vivax and P. falciparum)
and adults (2.6% and 14.2%, respectively, for P. vivax and
P. falciparum). Children and adolescents appear to be
more prone to P. vivax infection than adults, and the
reason for this is not known. One possible explanation is
that P. vivax can stay dormant in the liver of the adults for
a longer time and remain undetected at the time of
sample collection. Also, the difference in the level of
immunity between children/adolescents and adults
may in part influence the invasive capability of the
malaria parasite species [45].Conclusion
This study provides evidence for P. vivax infection in
Duffy-negative individuals in Ethiopia and the findings
on epidemiology offer evidence-based guidelines for
targeting disease control efforts in the most malarious
areas of the country.Additional files
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